Now that you know her HPV status, shouldn’t you know her FHACT®?

Take the guess work out of cervical cancer detection. FHACT® can help identify women most at risk for cervical cancer.

Women diagnosed with a low grade squamous intraepithelial lesion (LSIL) have a marginally higher risk of progression and hrHPV testing does not allow any additional benefit in risk assessment since most are hrHPV-positive. It is in these clinical settings affecting over 2 million women per year in the US, integration of additional biomarkers in the triage process is much needed in order to limit unnecessary colposcopies and excisional procedures and to identify those women with lesions that are at risk of progressing to a higher grade.

Register to our next Live Webinar Session on March 18th, 2015 at 12pm EST.





*required fields

I am text block. Click edit button to change this text.